Factors Affecting Citizen Trust and Public Engagement Relating to the Generation and Use of Real-World Evidence in Healthcare

The potential for the use of real-world data (RWD) to generate real-world evidence (RWE) that can inform clinical decision-making and health policy is increasingly recognized, albeit with hesitancy in some circles. If used appropriately, the rapidly expanding wealth of health data could improve healthcare research, delivery of care, and patient outcomes. However, this depends on two key factors: (1) building structures that increase the confidence and willingness of European Union (EU) citizens to permit the collection and use of their data, and (2) development of EU health policy to support and shape data collection infrastructures, methodologies, transmission, and use. The great potential for use of RWE in healthcare improvement merits careful exploration of the drivers of, and challenges preventing, efficient RWD curation. Literature-based research was performed to identify relevant themes and discussion topics for two sets of expert panels, organized by the European Alliance for Personalised Medicine. These expert panels discussed steps that would enable a gradual but steady growth in the quantity, quality, and beneficial deployment of RWE. Participants were selected to provide insight based on their professional medical, economic, patient, industry, or governmental experience. Here, we propose a framework that addresses public trust and access to data, cross-border governance, alignment of evidence frameworks, and demonstrable improvements in healthcare decisions. We also discuss key case studies that support these recommendations, in accordance with the discussions at the expert panels.

[1]  R. Chilton,et al.  Real-world evidence and product development: Opportunities, challenges and risk mitigation , 2021, Wiener klinische Wochenschrift.

[2]  A. Gajra,et al.  Use of Real-World Evidence to Support FDA Approval of Oncology Drugs. , 2020, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[3]  Elizabeth M. Hechenbleikner,et al.  Data explosion during COVID-19: A call for collaboration with the tech industry & data scrutiny , 2020, EClinicalMedicine.

[4]  M. P. Douglas,et al.  Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing-Based Tests: Challenges, Opportunities, and Potential Solutions. , 2020, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[5]  Dane Dickson,et al.  The Master Observational Trial: A New Class of Master Protocol to Advance Precision Medicine , 2020, Cell.

[6]  S. Sleijfer,et al.  The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs , 2019, Nature.

[7]  Alison Cave,et al.  Real‐World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe , 2019, Clinical pharmacology and therapeutics.

[8]  W. Mackillop,et al.  Real-world data: towards achieving the achievable in cancer care , 2019, Nature Reviews Clinical Oncology.

[9]  Hun-Sung Kim,et al.  Real-world Evidence versus Randomized Controlled Trial: Clinical Research Based on Electronic Medical Records , 2018, Journal of Korean medical science.

[10]  E. Perfetto,et al.  PEER-REVIEWED JOURNAL EDITORS’ VIEWS ON REAL-WORLD EVIDENCE , 2018, International Journal of Technology Assessment in Health Care.

[11]  A. Kent,et al.  EU Health Policy, Coherence, Stakeholder Diversity and Their Impact on the EMA , 2017, Biomedicine Hub.

[12]  D. Lacombe,et al.  Diverging EU health regulations: The urgent need for co ordination and convergence , 2017, Journal of Cancer Policy.

[13]  H. Hillege,et al.  Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies. , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[14]  P. Franklin Public health within the EU policy space: a qualitative study of Organized Civil Society (OCS) and the Health in All Policies (HiAP) approach. , 2016, Public health.

[15]  Erik Schultes,et al.  The FAIR Guiding Principles for scientific data management and stewardship , 2016, Scientific Data.

[16]  E. D. Gregorio The path forward. , 2015 .

[17]  T. Sudhop,et al.  A 1-year cross-sectional analysis of non-interventional post-marketing study protocols submitted to the German Federal Institute for Drugs and Medical Devices (BfArM) , 2013, European Journal of Clinical Pharmacology.

[18]  서정헌,et al.  반도체 공정 overview , 2001 .

[19]  Captain Y. B. Nusfield,et al.  Public Health , 1906, Canadian Medical Association journal.

[20]  Charline Morichon EUROPE'S BEATING CANCER PLAN , 2020 .

[21]  EU guidelines on ethics in artificial intelligence : Context and implementation , 2019 .